Successful T cell engineering with gene scissors
The idea of genetically modifying a patient’s own immune cells and deploying them against infections and tumors has been around since the 1980s. But to this day modified T cells are still not as effective as natural T cells and have been only been of limited clinical value. Using the new CRISPR-Cas9 gene editing tool, a team at the Technical University of Munich (TUM) has now engineered T cells that are very similar to physiological immune cells.
There are two forms of T cell therapy: either a recipient receives cells from a donor, or the recipient’s own T cells are removed, genetically reprogrammed in a laboratory and unleashed against an infection or tumor in the body. While the first method has proven to be successful in clinical models, reprogramming T cells is still beset with problems.
The team led by Professor Dirk Busch, Director of the Institute for Medical Microbiology, Immunology and Hygiene at the TUM, has generated modified T cells for the first time that are very similar to their natural counterparts and could solve some of those problems. To do so, they utilized the new CRISPR-Cas9 gene scissors, which can be used to snip out and replace targeted segments of the genome.
Both the conventional methods and the new method target the key homing instrument of T cells, known as the T cell receptor. The receptor, residing on the cell’s surface, recognizes specific antigens associated with pathogens or tumor cells, which the T cell is then able to attack. Each receptor is made up of two molecular chains that are linked together. The genetic information for the chains can be genetically modified to produce new receptors that are able to recognize any desired antigen. In this way, it is possible to reprogram T cells.
Targeted exchange using the CRISPR-Cas9 gene scissors
The problem with conventional methods is that the genetic information for the new receptors is randomly inserted into the genome. This means that T cells are produced with both new and old receptors or with receptors having one old and one new chain. As a result, the cells do not function as effectively as physiological T cells and are also controlled differently. Moreover, there is a danger that the mixed chains could trigger dangerous side effects (Graft-versus-Host Disease, GvHD).
“Using the CRISPR method, we’ve been able to completely replace the natural receptors with new ones, because we’re able to insert them into the very same location in the genome. In addition, we’ve replaced the information for both chains so that there are no longer any mixed receptors,” explains Kilian Schober, who is a lead author of the new study along with his colleague Thomas Müller.
Near-natural properties
Thomas Müller explains the advantages of the modified T cells: “They’re much more similar to physiological T cells, yet they can be changed flexibly. They’re controlled like physiological cells and have the same structure, but are capable of being genetically modified.“ The scientists have demonstrated in a cell culture model that T cells modified in this way behave nearly exactly like their natural counterparts.
“Another advantage is that the new method allows multiple T cells to be modified simultaneously so that they’re able to recognize different targets and can be used in combination. This is especially interesting for cancer therapy, because tumors are highly heterogeneous,” Dirk Busch adds. In the future, the team plans to investigate the new cells and their properties in preclinical mouse models, an important step in preparing for clinical trials with humans.
Learn more: Successful T cell engineering with gene scissors
The Latest on: CRISPR-Cas9 gene scissors
[google_news title=”” keyword=”CRISPR-Cas9 gene scissors” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR-Cas9 gene scissors
- Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trialon May 13, 2024 at 1:06 pm
Mass Eye and Ear-led phase 1/2 trial, which included 14 participants, found that the first-of-its-kind experimental treatment was safe and efficacious. BRILLIANCE trial results showed 11 out of 14 ...
- CRISPR-based gene editing treatment shows promise for rare eye disorderon May 9, 2024 at 8:08 am
Researchers at Oregon Health & Science University used an experimental CRISPR-based gene editing treatment in participants with a rare eye disorder that causes low vision and blindness. The results ...
- Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Icebergon May 9, 2024 at 6:32 am
Crispr Therapeutics AG shows potential for future earnings with its gene editing therapy Casgevy, offering treatment for various diseases. Read more here.
- CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approachon May 8, 2024 at 12:00 am
CTX340™ and CTX450™ utilize LNP-based delivery of CRISPR/Cas9 gene editing cargo to the liver, targeting angiotensinogen (AGT) for refractory hypertension and 5’-aminolevulinate synthase 1 (ALAS1) for ...
- Microbiome studies help explore treatments for genetic disorderson May 7, 2024 at 6:31 am
A collaboration has led to the identification, in a bacterium of the intestine, of new CRISPR-Cas9 molecules that could have a clinical potential to treat genetic diseases such as retinitis pigmentosa ...
- CRISPR gene editing shows promise for treating individuals with a form of inherited blindnesson May 6, 2024 at 12:03 pm
Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the ...
- CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical trial showson May 6, 2024 at 9:14 am
Results of a phase 1/2 clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the ...
- Clinical trial shows measurable improvement in inherited blindness after gene therapyon May 6, 2024 at 8:19 am
An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindness, an early-stage clinical trial says.
- Experimental gene therapy restores some vision in patients with inherited blindnesson May 6, 2024 at 7:32 am
“The results of this study provide proof of concept that CRISPR-Cas9 gene editing can be used safely and effectively to treat inherited retinal disorders,” said the study’s first author Dr ...
- CRISPR gene therapy improves vision in people with inherited blindnesson May 6, 2024 at 6:06 am
Phase 1/2 trial of Brilliance showed promising results in vision improvement in people with inherited retinal disorders.
via Bing News